Oncology MoA Animation
We created this mechanism of action (MoA) animation for Novartis for their oncology product, TABRECTA™. TABRECTA™ (capmatinib) tablets are indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC), whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping.
This medical animation, based on in vitro/in vivo studies, uses scientific storytelling to explain the action of TABRECTA™ tablets. The animation uses eye-catching visuals to captivate and engage the viewer. The animation explains METex14 in NSCLC, the role of MET in cell signaling, and capmatinib’s MoA.
TABRECTA™ is a kinase inhibitor, operating by blocking a key enzyme that results in helping to stop the tumor cells from growing. This treatment is intended for patients who have NSCLC that has spread to other parts of the body or cannot be removed by surgery, and whose tumors have an abnormal mesenchymal-epithelial transition (MET) gene.
This animation is featured online as part of the Novartis website intended for Healthcare professionals (HCPs).
The animation is hosted on the TABRECTA™ product page for HCPs to learn more about the product, where they can explore related product resources such as the efficacy, safety profile, product dosing, and administration.
View full animation below.